Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.77 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.77 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.77 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.77 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.77 |
| ▸ | ATIC | P31939 | 3/20 | 0.77 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.77 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.77 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.77 |
| ▸ | FRK | P42685 | 1/20 | 0.77 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL6034765 | 1.00 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7968 | 1.00 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7969 | 1.00 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15648731 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124673 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL108860 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL126068 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL3388816 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL19411240 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124663 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478632-B | Novel crystal form of pemetrexed diacid and preparation method thereof | 江苏豪森药业集团有限公司 | 2020-11-27 | — | — | CN | claimed |
| CN-102056609-B | Pharmaceutical combination | BOEHRINGER INGELHEIM INT | 2012-12-05 | — | — | CN | claimed |
| EP-3675819-B1 | STABLE LIQUID COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LTD (IN) | 2026-01-14 | — | — | EP | disclosed |
| US-20220151923-A1 | STABLE LIQUID COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-109152778-B | Pemetrexed preparation | 鹰制药股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-112043829-A | Treatment and prognostic monitoring of proliferative disorders using HEDGEHOG pathway inhibitors | 梅恩医药国际有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-106478632-B | Novel crystal form of pemetrexed diacid and preparation method thereof | 江苏豪森药业集团有限公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-2020207397-A1 | METHOD FOR PURIFYING PEMETREXED INTERMEDIATE | 重庆迈德凯医药有限公司 | 2020-10-15 | — | — | WO | disclosed |
| US-10792285-B2 | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-10-06 | — | — | US | disclosed |
| US-10792285-B2 | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-10-06 | — | — | US | disclosed |
| WO-2015089068-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OF FETAL CELLS | ANALIZA, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2014198337-A1 | STABLE AND WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING PEMETREXED | SYNTHON B.V. (NL) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198338-A1 | STABLE PEMETREXED ARGININE SALT AND COMPOSITIONS COMPRISING IT | SYNTHON B.V. (NL) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014084651-A1 | A STABILIZED PEMETREXED FORMULATION | CJ HEALTHCARE CORPORATION (KR) | 2014-06-05 | — | — | WO | disclosed |
| US-8362245-B2 | Processes for preparing intermediates of pemetrexed | SICOR INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102056609-B | Pharmaceutical combination | BOEHRINGER INGELHEIM INT | 2012-12-05 | — | — | CN | disclosed |
| US-20110263851-A1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | SICOR INC. (US) | 2011-10-27 | — | — | US | disclosed |
| CN-101325955-A | Methods of treating cancer with SAHA and pemetrexed | MERCK & CO INC (US) | 2008-12-17 | — | — | CN | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792285-B2 | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | MTHFD1, TYMP, TYMS | GART 23/4885DHFR 6/4885TYMS 3/4885 |
| US-20110263851-A1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | DPYD, TYMP, TYMS | GART 193/4885DHFR 5/4885TYMS 3/4885 |
| US-20220151923-A1 | STABLE LIQUID COMPOSITIONS OF PEMETREXED | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DCTD, PDCD5 | GART 130/4885DHFR 101/4885TYMS 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.